Akums Drugs & Pharmaceuticals Ltd is a mid‑cap pharmaceutical contract development and manufacturing organization (CDMO), incorporated in 2004 and headquartered in New Delhi. It is India’s largest CDMO, catering to formulations across pharmaceuticals, nutraceuticals, cosmetics, and dermatology.
Promoter: The founding team continues to lead Akums, positioning it as a trusted partner for both domestic and multinational pharma companies.
FY22–FY25 Snapshot
Sales – ₹3,420 Cr → ₹3,780 Cr → ₹4,210 Cr → ₹4,560 Cr
Net Profit – ₹265 Cr → ₹310 Cr → ₹355 Cr → ₹402 Cr
Operating Performance – Moderate → Strong → Very Strong → Excellent
Dividend Yield – 0.0% (company reinvests earnings into growth)
Equity Capital – ₹146 Cr (post‑IPO listing in FY25)
Total Debt – ₹1,020 Cr → ₹940 Cr → ₹810 Cr → ₹720 Cr (steady deleveraging)
Fixed Assets – ₹1,850 Cr → ₹1,910 Cr → ₹1,980 Cr → ₹2,050 Cr
EPS (TTM) – ₹8.9 → ₹9.7 → ₹10.2 → ₹11.0
Institutional Interest & Ownership Trends
Promoter holding: ~55%, reflecting strong family control.
FIIs/DIIs: Rising interest post‑IPO, with DIIs adding exposure to India’s CDMO growth story.
Public float: ~45%, with delivery volumes showing accumulation by long‑term investors.
Strategic Moves & Innovations
Expansion in pharma formulations across tablets, injectables, and biologics.
Diversification into nutraceuticals, cosmetics, and dermatology.
Focus on global certifications (EU‑GMP, WHO) to expand exports.
Investment in R&D and regulatory compliance to strengthen CDMO positioning.
Cash Flow & Balance Sheet Strength
Operating cash flows strengthened in FY25, supported by higher utilization of manufacturing facilities.
Free cash flow positive, reinvested into capacity expansion and modernization.
Debt reduced steadily, improving balance sheet resilience.
Strong asset base with multiple manufacturing plants across India.
Risk Factors
Dependence on regulatory approvals and compliance standards.
Margin sensitivity to raw material costs and pricing pressure from clients.
Competition from global CDMOs and Indian peers.
Currency risks due to export exposure.
Investor Takeaway
Akums Drugs & Pharmaceuticals Ltd. demonstrates steady revenue growth, margin expansion, and deleveraging, supported by its leadership in India’s CDMO space and diversification into nutraceuticals and cosmetics. With strong institutional interest post‑IPO and global certifications, it is well‑positioned for sustained growth, though investors should monitor regulatory and competitive risks.
Promoter: The founding team continues to lead Akums, positioning it as a trusted partner for both domestic and multinational pharma companies.
FY22–FY25 Snapshot
Sales – ₹3,420 Cr → ₹3,780 Cr → ₹4,210 Cr → ₹4,560 Cr
Net Profit – ₹265 Cr → ₹310 Cr → ₹355 Cr → ₹402 Cr
Operating Performance – Moderate → Strong → Very Strong → Excellent
Dividend Yield – 0.0% (company reinvests earnings into growth)
Equity Capital – ₹146 Cr (post‑IPO listing in FY25)
Total Debt – ₹1,020 Cr → ₹940 Cr → ₹810 Cr → ₹720 Cr (steady deleveraging)
Fixed Assets – ₹1,850 Cr → ₹1,910 Cr → ₹1,980 Cr → ₹2,050 Cr
EPS (TTM) – ₹8.9 → ₹9.7 → ₹10.2 → ₹11.0
Institutional Interest & Ownership Trends
Promoter holding: ~55%, reflecting strong family control.
FIIs/DIIs: Rising interest post‑IPO, with DIIs adding exposure to India’s CDMO growth story.
Public float: ~45%, with delivery volumes showing accumulation by long‑term investors.
Strategic Moves & Innovations
Expansion in pharma formulations across tablets, injectables, and biologics.
Diversification into nutraceuticals, cosmetics, and dermatology.
Focus on global certifications (EU‑GMP, WHO) to expand exports.
Investment in R&D and regulatory compliance to strengthen CDMO positioning.
Cash Flow & Balance Sheet Strength
Operating cash flows strengthened in FY25, supported by higher utilization of manufacturing facilities.
Free cash flow positive, reinvested into capacity expansion and modernization.
Debt reduced steadily, improving balance sheet resilience.
Strong asset base with multiple manufacturing plants across India.
Risk Factors
Dependence on regulatory approvals and compliance standards.
Margin sensitivity to raw material costs and pricing pressure from clients.
Competition from global CDMOs and Indian peers.
Currency risks due to export exposure.
Investor Takeaway
Akums Drugs & Pharmaceuticals Ltd. demonstrates steady revenue growth, margin expansion, and deleveraging, supported by its leadership in India’s CDMO space and diversification into nutraceuticals and cosmetics. With strong institutional interest post‑IPO and global certifications, it is well‑positioned for sustained growth, though investors should monitor regulatory and competitive risks.
Sucrit.D.Patil
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน
Sucrit.D.Patil
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน